Trial Profile
Vedolizumab effect on liver biochemistry in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease .
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Inflammatory bowel diseases; Primary sclerosing cholangitis
- Focus Therapeutic Use
- 01 Feb 2018 New trial record
- 29 Jan 2018 Results published in the Alimentary Pharmacology and Therapeutics.